[Initial trial of tumor imaging using 123I-BMIPP: evaluation in soft tissue tumors].
To evaluate the usefulness of 123I-15-(p-iodophenyl)-3 (R, S)-methyl-pentadecanoic acid (123I-BMIPP) as a radiopharmaceutical for tumor imaging, six patients with liposarcomas and one patient with malignant fibrous histiocytoma were studied with 123I-BMIPP. 123I-BMIPP accumulated in the myxoid components of liposarcoma, while the well-differentiated components showed no increased uptake of 123I-BMIPP. 123I-BMIPP accumulated in viable parts of the tumor, while there was no uptake in the necrotic parts in one patient with malignant fibrous histiocytoma. This study indicated that 123I-BMIPP may be a special radiopharmaceutical for tumor imaging.
Tanabe
Y
Y
Department of Radiology, Tottori University School of Medicine.
Suto
Y
Y
Ohta
Y
Y
D000328:Adult; D000368:Aged; D005227:Fatty Acids; D005260:Female; D018219:Histiocytoma, Benign Fibrous / Q000000981:diagnostic imaging; D006801:Humans; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D008080:Liposarcoma / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012983:Soft Tissue Neoplasms / Q000000981:diagnostic imaging*
D005227:Fatty Acids; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019275:Radiopharmaceuticals; C049338:iodofiltic acid